A Breakthrough in Melanoma Treatment


August 24, 2011

NBC 10

Ravi Amaravadi, MD, an assistant professor of Hematology-Oncology in the Abramson Cancer Center, is quoted in an NBC10 story about last week's FDA approval of Zelboraf, a targeted therapy for metastatic melanoma which attacks a mutated form of a gene called BRAF, which is carried by about 50 percent of all melanoma patients. It is the second drug to be approved for the disease this year, bringing new hope to patients who have had few new treatment options in more than a decade. An Abramson Cancer Center patient who has been taking the drug for two months is also featured in the story, noting that after six years of treatment for the disease, seeing "positive progress" on her scans so quickly gives her new hope. Watch Segment